Abstract
Hepatocellular carcinoma (HCC) is the predominant type of liver cancer and a leading cause of cancer-related death globally. It is also a sexually dimorphic disease with a male predominance both in HCC and in its precursors, non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH). The role of the androgen receptor (AR) in HCC has been well documented; however, AR-targeted therapies have failed to demonstrate efficacy in HCC. Building upon understandings of AR in prostate cancer (PCa), this review examines the role of AR in HCC, non-androgen-mediated mechanisms of induced AR expression, the existence of AR splice variants (AR-SV) in HCC and concludes by surveying current AR-targeted therapeutic approaches in PCa that show potential for efficacy in HCC in light of AR-SV expression.
Funder
Ohio State University College of Pharmacy Dean’s Innovation Award
The Ohio State University Comprehensive Cancer Center
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference106 articles.
1. Hepatocellular carcinoma;Llovet;Nat. Rev. Dis. Prim.,2021
2. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma;Zhang;Drug Discov. Today,2021
3. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH);Burra;Liver Int.,2021
4. Bethesda, M.D. SEER Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. 2022.
5. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers;Kanda;World J. Gastroenterol.,2014
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献